These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38484555)

  • 21. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
    Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
    Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.
    He J; Cheng J; Guan Q; Yan H; Li Y; Zhao W; Guo Z; Wang X
    Cancer Sci; 2020 Jan; 111(1):253-265. PubMed ID: 31785020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
    Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
    Oncology; 2011; 80(1-2):84-91. PubMed ID: 21677451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Konishi T; Horie H; Ikeuchi H; Eshima K; Muto T
    Clin Transl Oncol; 2011 Jun; 13(6):419-25. PubMed ID: 21680303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].
    Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
    Gan To Kagaku Ryoho; 2011 Oct; 38(10):1627-32. PubMed ID: 21996957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
    Lin L; Zhang Z; Zhang W; Wang L; Wang J
    Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Angitapalli R; Litwin AM; Kumar PR; Nasser E; Lombardo J; Mashtare T; Wilding GE; Fakih MG
    Oncology; 2009; 76(5):363-8. PubMed ID: 19321964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study.
    Aloysius MM; Zaitoun AM; Beckingham IJ; Neal KR; Aithal GP; Bessell EM; Lobo DN
    Virchows Arch; 2007 Nov; 451(5):943-8. PubMed ID: 17805566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study.
    Badary DM; Elkabsh MM; Mady HH; Gabr A; Kroosh SS
    Appl Immunohistochem Mol Morphol; 2020; 28(10):741-747. PubMed ID: 32118594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
    Lin PC; Lin HH; Lin JK; Lin CC; Yang SH; Li AF; Chen WS; Chang SC
    Int J Biol Markers; 2013 Jun; 28(2):182-6. PubMed ID: 23558935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer.
    Kim S; Kang SI; Kim S; Kim JH
    J Surg Res; 2021 Nov; 267():391-396. PubMed ID: 34218138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Moreau LC; Rajan R; Thirlwell MP; Alcindor T
    Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.
    des Guetz G; Mariani P; Cucherousset J; Benamoun M; Lagorce C; Sastre X; Le Toumelin P; Uzzan B; Perret GY; Morere JF; Breau JL; Fagard R; Schischmanoff PO
    Anticancer Res; 2007; 27(4C):2715-9. PubMed ID: 17695437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to FOLFOX.
    Sawayama H; Hayashi N; Honda S; Baba Y; Toyama E; Watanabe M; Takamori H; Beppu T; Baba H
    Int J Clin Oncol; 2010 Feb; 15(1):70-6. PubMed ID: 20087616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?
    Suenaga M; Matsusaka S; Watanabe T; Kuboki Y; Shinozaki E; Chin K; Mizunuma N; Ueno M; Yamaguchi T; Hatake K
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):129-35. PubMed ID: 21585692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
    Wasan HS; Gibbs P; Sharma NK; Taieb J; Heinemann V; Ricke J; Peeters M; Findlay M; Weaver A; Mills J; Wilson C; Adams R; Francis A; Moschandreas J; Virdee PS; Dutton P; Love S; Gebski V; Gray A; ; ; ; van Hazel G; Sharma RA
    Lancet Oncol; 2017 Sep; 18(9):1159-1171. PubMed ID: 28781171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
    Nagourney RA; Evans S; Tran PH; Nagourney AJ; Sugarbaker PH
    Eur J Surg Oncol; 2021 Apr; 47(4):738-742. PubMed ID: 33004272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
    Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
    Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.